Skip to content

Ascendis Pharma A/S

US · ASND #1127 by market cap Listed 2015
228.41 +2.36 +1.04%
Live - 5344 symbols - heartbeat 388s ago · 2026-10-08 07:01
Pre-market 229.00 +0.26%
After-hours 228.41 0.00%
Overnight 229.84 +0.63%
Market cap
15.03B
P/B
9.35
EPS
-4.21
Reader sentiment Are you bullish or bearish on ASND?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    BMO Capital Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $319
    Market Newswire · 2026/8/19
  • Rating change
    A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344
    Market Newswire · 2026/9/2
  • Rating change
    Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345
    Market Newswire · 2026/8/7
  • Rating change
    Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $275
    Market Newswire · 2026/7/23
  • Raymond James Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $287
    Market Newswire · 2026/9/15
  • Rating change
    H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $344
    Market Newswire · 2026/8/31
  • Rating change
    H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $344
    Market Newswire · 2026/9/10
  • Rating change
    Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329
    Market Newswire · 2026/8/8
  • Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $327
    Market Newswire · 2026/9/17
  • Rating change
    Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275
    Market Newswire · 2026/8/31
  • Rating change
    A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $326 to $360
    Market Newswire · 2026/8/14
  • Rating change
    Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $300
    Market Newswire · 2026/8/8
  • Rating change
    J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $300
    Market Newswire · 2026/8/20
  • Rating change
    Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312
    Market Newswire · 2026/9/3
  • Rating change
    H.C. Wainwright Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $345
    Market Newswire · 2026/8/27
  • Rating change
    A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $275 to $360
    Market Newswire · 2026/8/15
  • Rating change
    Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $300
    Market Newswire · 2026/7/27
  • A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $304 to $344
    Market Newswire · 2026/9/16
  • Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273
    Market Newswire · 2026/9/28
  • Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329
    Market Newswire · 2026/9/30

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:01:58 · For reference only, not investment advice and not tailored to your situation.